ATE401088T1 - Zusammensetzung mit einem survivin-antisense- oligonucleotid und gemcitabin zur behandlung von krebs - Google Patents
Zusammensetzung mit einem survivin-antisense- oligonucleotid und gemcitabin zur behandlung von krebsInfo
- Publication number
- ATE401088T1 ATE401088T1 AT05738307T AT05738307T ATE401088T1 AT E401088 T1 ATE401088 T1 AT E401088T1 AT 05738307 T AT05738307 T AT 05738307T AT 05738307 T AT05738307 T AT 05738307T AT E401088 T1 ATE401088 T1 AT E401088T1
- Authority
- AT
- Austria
- Prior art keywords
- cancer
- antisense oligonucleotide
- gemcitabine
- treatment
- composition
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 108091034117 Oligonucleotide Proteins 0.000 title abstract 2
- 102000000763 Survivin Human genes 0.000 title abstract 2
- 108010002687 Survivin Proteins 0.000 title abstract 2
- 239000000074 antisense oligonucleotide Substances 0.000 title abstract 2
- 238000012230 antisense oligonucleotides Methods 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 title 1
- 229960005277 gemcitabine Drugs 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56454004P | 2004-04-22 | 2004-04-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE401088T1 true ATE401088T1 (de) | 2008-08-15 |
Family
ID=35094133
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05738307T ATE401088T1 (de) | 2004-04-22 | 2005-04-15 | Zusammensetzung mit einem survivin-antisense- oligonucleotid und gemcitabin zur behandlung von krebs |
| AT07119706T ATE538800T1 (de) | 2004-04-22 | 2005-04-15 | Kombinationstherapie zur krebsbehandlung |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07119706T ATE538800T1 (de) | 2004-04-22 | 2005-04-15 | Kombinationstherapie zur krebsbehandlung |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US20070244065A1 (de) |
| EP (3) | EP1763356B1 (de) |
| JP (1) | JP2007533742A (de) |
| CN (2) | CN101683355A (de) |
| AT (2) | ATE401088T1 (de) |
| AU (1) | AU2005240020B2 (de) |
| BR (1) | BRPI0509927A (de) |
| CA (1) | CA2562750A1 (de) |
| CY (2) | CY1110440T1 (de) |
| DE (1) | DE602005008241D1 (de) |
| DK (2) | DK1763356T3 (de) |
| ES (2) | ES2376484T3 (de) |
| MX (1) | MXPA06012132A (de) |
| PL (2) | PL1763356T3 (de) |
| PT (2) | PT1913947E (de) |
| SI (2) | SI1913947T1 (de) |
| WO (1) | WO2005107771A2 (de) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3266453A1 (de) * | 2008-07-03 | 2018-01-10 | Mayo Foundation for Medical Education and Research | Krebsbehandlung |
| FR2955112B1 (fr) | 2010-01-14 | 2012-01-20 | Isp Investments Inc | Nouveaux peptides anti-age modulateurs de la survivine et compositions les comprenant |
| WO2012058462A2 (en) * | 2010-10-29 | 2012-05-03 | Isis Pharmaceuticals, Inc. | Combination therapy for the treatment of cancer |
| PT2707030T (pt) | 2011-05-09 | 2020-05-22 | Mayo Found Medical Education & Res | Tratamentos de cancro |
| WO2014055415A1 (en) | 2012-10-01 | 2014-04-10 | Mayo Foundation For Medical Education And Research | Cancer treatments |
| CA2952424C (en) | 2014-06-16 | 2019-07-23 | Mayo Foundation For Medical Education And Research | Treating myelomas |
| US9446148B2 (en) | 2014-10-06 | 2016-09-20 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
| TW201707725A (zh) | 2015-08-18 | 2017-03-01 | 美國馬友醫藥教育研究基金會 | 載體－抗體組合物及其製造及使用方法 |
| TW201713360A (en) | 2015-10-06 | 2017-04-16 | Mayo Foundation | Methods of treating cancer using compositions of antibodies and carrier proteins |
| US11571469B2 (en) | 2016-01-07 | 2023-02-07 | Mayo Foundation For Medical Education And Research | Methods of treating cancer with interferon wherein the cancer cells are HLA negative or have reduced HLA expression |
| AU2017217881B2 (en) | 2016-02-12 | 2022-11-17 | Mayo Foundation For Medical Education And Research | Hematologic cancer treatments |
| EP3432928A4 (de) | 2016-03-21 | 2019-11-20 | Mayo Foundation for Medical Education and Research | Verfahren zur verbesserung des therapeutischen index für ein chemotherapeutikum |
| AU2017238119A1 (en) | 2016-03-21 | 2018-10-11 | Mayo Foundation For Medical Education And Research | Methods for reducing toxicity of a chemotherapeutic drug |
| US10618969B2 (en) | 2016-04-06 | 2020-04-14 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
| WO2018045238A1 (en) | 2016-09-01 | 2018-03-08 | Mayo Foundation For Medical Education And Research | Methods and compositions for targeting t-cell cancers |
| EP3506942B1 (de) | 2016-09-01 | 2022-11-16 | Mayo Foundation for Medical Education and Research | Carrier-pd-l1-bindende wirkstoffzusammensetzungen zur behandlung von krebs |
| AU2017324335A1 (en) | 2016-09-06 | 2019-03-28 | Mayo Foundation For Medical Education And Research | Methods of treating PD-L1 expressing cancer |
| AU2017324947A1 (en) | 2016-09-06 | 2019-03-28 | Mayo Foundation For Medical Education And Research | Paclitaxel-albumin-binding agent compositions and methods for using and making the same |
| EP3509635A1 (de) | 2016-09-06 | 2019-07-17 | Vavotar Life Sciences LLC | Verfahren zur behandlung von dreifach negativem brustkrebs unter verwendung von zusammensetzungen aus antikörpern und trägerproteinen |
| CA3156667A1 (en) * | 2019-10-02 | 2021-04-08 | Sirnaomics, Inc. | OLIGONUCLEOTIDES INCLUDING NUCLEOSIDE ANALOGS |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1264738A (en) * | 1984-12-04 | 1990-01-23 | Eli Lilly And Company | Treatment of tumors in mammals |
| US6335194B1 (en) * | 1998-09-29 | 2002-01-01 | Isis Pharmaceuticals, Inc. | Antisense modulation of survivin expression |
| US6077709A (en) * | 1998-09-29 | 2000-06-20 | Isis Pharmaceuticals Inc. | Antisense modulation of Survivin expression |
| US6838283B2 (en) * | 1998-09-29 | 2005-01-04 | Isis Pharmaceuticals Inc. | Antisense modulation of survivin expression |
| MXPA05008319A (es) * | 2003-02-10 | 2006-02-28 | Santaris Pharma As | Compuestos oligomericos para la modulacion de la expresion de survivina. |
-
2005
- 2005-04-15 PL PL05738307T patent/PL1763356T3/pl unknown
- 2005-04-15 PT PT07119706T patent/PT1913947E/pt unknown
- 2005-04-15 DK DK05738307T patent/DK1763356T3/da active
- 2005-04-15 EP EP05738307A patent/EP1763356B1/de not_active Not-in-force
- 2005-04-15 MX MXPA06012132A patent/MXPA06012132A/es active IP Right Grant
- 2005-04-15 PL PL07119706T patent/PL1913947T3/pl unknown
- 2005-04-15 ES ES07119706T patent/ES2376484T3/es active Active
- 2005-04-15 DE DE602005008241T patent/DE602005008241D1/de active Active
- 2005-04-15 EP EP07119706A patent/EP1913947B1/de not_active Not-in-force
- 2005-04-15 CN CN200910163328A patent/CN101683355A/zh active Pending
- 2005-04-15 AT AT05738307T patent/ATE401088T1/de active
- 2005-04-15 JP JP2007509532A patent/JP2007533742A/ja active Pending
- 2005-04-15 ES ES05738307T patent/ES2308488T3/es active Active
- 2005-04-15 EP EP09168514A patent/EP2145626A1/de not_active Withdrawn
- 2005-04-15 PT PT05738307T patent/PT1763356E/pt unknown
- 2005-04-15 BR BRPI0509927-7A patent/BRPI0509927A/pt not_active IP Right Cessation
- 2005-04-15 AU AU2005240020A patent/AU2005240020B2/en not_active Ceased
- 2005-04-15 US US11/587,219 patent/US20070244065A1/en not_active Abandoned
- 2005-04-15 SI SI200531449T patent/SI1913947T1/sl unknown
- 2005-04-15 CN CNA2005800118267A patent/CN1950094A/zh active Pending
- 2005-04-15 DK DK07119706.5T patent/DK1913947T3/da active
- 2005-04-15 CA CA002562750A patent/CA2562750A1/en not_active Abandoned
- 2005-04-15 WO PCT/US2005/012968 patent/WO2005107771A2/en active Application Filing
- 2005-04-15 SI SI200530382T patent/SI1763356T1/sl unknown
- 2005-04-15 AT AT07119706T patent/ATE538800T1/de active
-
2008
- 2008-09-24 CY CY20081101036T patent/CY1110440T1/el unknown
-
2009
- 2009-03-13 US US12/403,561 patent/US20090247611A1/en not_active Abandoned
-
2011
- 2011-09-28 US US13/246,890 patent/US20120022140A1/en not_active Abandoned
-
2012
- 2012-02-24 CY CY20121100197T patent/CY1112397T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT1913947E (pt) | 2012-01-19 |
| US20120022140A1 (en) | 2012-01-26 |
| WO2005107771A2 (en) | 2005-11-17 |
| EP1763356B1 (de) | 2008-07-16 |
| DK1763356T3 (da) | 2008-10-13 |
| CN101683355A (zh) | 2010-03-31 |
| EP2145626A1 (de) | 2010-01-20 |
| DE602005008241D1 (de) | 2008-08-28 |
| CY1112397T1 (el) | 2015-12-09 |
| ATE538800T1 (de) | 2012-01-15 |
| CY1110440T1 (el) | 2015-04-29 |
| MXPA06012132A (es) | 2007-01-17 |
| SI1913947T1 (sl) | 2012-02-29 |
| JP2007533742A (ja) | 2007-11-22 |
| AU2005240020B2 (en) | 2011-02-10 |
| CN1950094A (zh) | 2007-04-18 |
| WO2005107771A3 (en) | 2006-06-08 |
| EP1913947B1 (de) | 2011-12-28 |
| PL1763356T3 (pl) | 2008-12-31 |
| ES2376484T3 (es) | 2012-03-14 |
| SI1763356T1 (sl) | 2008-12-31 |
| AU2005240020A1 (en) | 2005-11-17 |
| DK1913947T3 (da) | 2012-02-06 |
| ES2308488T3 (es) | 2008-12-01 |
| US20070244065A1 (en) | 2007-10-18 |
| BRPI0509927A (pt) | 2007-09-25 |
| EP1763356A2 (de) | 2007-03-21 |
| US20090247611A1 (en) | 2009-10-01 |
| EP1913947A1 (de) | 2008-04-23 |
| CA2562750A1 (en) | 2005-11-17 |
| PL1913947T3 (pl) | 2012-05-31 |
| PT1763356E (pt) | 2008-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE401088T1 (de) | Zusammensetzung mit einem survivin-antisense- oligonucleotid und gemcitabin zur behandlung von krebs | |
| ATE345130T1 (de) | Arylharnstoff-verbindungen in kombination mit anderen zytostatisch oder zytotoxisch wirksamen stoffen zur behandlungen menschlicher krebserkrankungen | |
| DE602006017965D1 (de) | Maleimid-derivate, pharmazeutische zusammensetzungen und verfahren zur behandlung von krebs | |
| EP1622608A4 (de) | Zusammensetzungen und verfahren zur behandlung von krebs | |
| MY162903A (en) | Methods of treatment of pancreatic cancer | |
| BRPI0511139B8 (pt) | compostos que inibem quinase aurora e composição farmacêutica contendo os mesmos | |
| MX2009006466A (es) | Metodos de tratamiento de cancer con inhibidores del receptor del factor 1 de crecimiento similar a la insulina. | |
| CY1111263T1 (el) | Φαρμακευτικη συνθεση η οποια περιλαμβανει sns-595 και χρησεις αυτης | |
| HK1137366A1 (en) | Pharmaceutical compositions comprising activin-actriia antagonists and use thereof in preventing or treating multiple myeloma | |
| BRPI0906181A2 (pt) | "método para tratamento de uma disfunção hiperproliferativa, composição farmacêutica, uso de uma combinação terapêutica na fabricação de um medicamento para o tratamento de câncer, artigo de fabricação para tratamento de uma disfunção hiperproliferativa, método para determinação de compostos a serem usados em combinação para o tratamento de câncer e método para determinação de uma combinação terapêutica a ser usada para o tratamento de câncer" | |
| PT2100614E (pt) | Antagonistas de receptor para tratamento de cancro ósseo metastático | |
| EA201791669A2 (ru) | Новые терапевтические подходы в лечении смт и связанных с ней расстройств | |
| EP1505990A4 (de) | Verfahren zur behandlung von hepatitis | |
| ATE525070T1 (de) | Silbininkomponente zur behandlung von hepatitis | |
| EA201200428A1 (ru) | Композиция и способ для лечения ожирения | |
| ATE459353T1 (de) | Gaboxadol zur behandlung von depressionen und anderen affektiven störungen | |
| EP4138843A4 (de) | Zusammensetzung zur behandlung von blutkrebs mit 4'-thio-5-aza-2'-deoxycytidin und verwendungen davon | |
| ATE473277T1 (de) | Zusammensetzungen und verfahren zur prävention und behandlung von immunvermittelten entzündungskrankheiten | |
| ATE522531T1 (de) | Indolylpyrrolidine zur behandlung von krebs | |
| DE602005020113D1 (de) | Verfahren zur behandlung von akuten rhinosinusitis | |
| ATE510530T1 (de) | Verfahren zur verhinderung und/oder behandlung von altersflecken | |
| DE60334289D1 (de) | Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen | |
| ATE537838T1 (de) | Kombinationstherapie mit kloretazin(tm) | |
| UA110795C2 (uk) | Спосіб лікування раку підшлункової залози | |
| TH137782A (th) | องค์ประกอบและวิธีการสำหรับ ป้องกันและรักษาโรคอัลไซเมอร์ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1763356 Country of ref document: EP |